Patient Guide to Support Services


YOU&i Support

Pharmacyclics, an AbbVie Company, together with Janssen Biotech, created a unique set of patient support programs called YOU&i Support. This is a personalized program that helps patients to access Imbruvica (ibrutinib), a Bruton kinase inhibitor; find affordability support options; and sign up for information and resources to support them during their treatment (Table).


This program will:

  • Contact patients’ insurance provider to help understand benefits
  • Find options to help patients afford their treatment
  • Provide educational information
  • Offer nurse call support and respond to questions.

YOU&i Instant Savings Program

For commercially insured patients, Pharmacyclics and Janssen Biotech offer the YOU&i Instant Savings Program to help with private insurance copay, deductible, and coinsurance costs for Imbruvica. This program enables eligible patients with commercial insurance to pay a $10 monthly co­pay for Imbruvica, regardless of income level.


To be eligible for the YOU&i Instant Savings Program, patients must:

  • Reside in the United States or Puerto Rico
  • Have been prescribed Imbruvica
  • Have commercial insurance
  • Not be enrolled in federal- or state-­subsidized healthcare programs that cover prescription drugs, including Medicare Part D, Medicare Advantage Plan, Medicaid, TRICARE, or any other federal or state healthcare plan, including pharmaceutical assistance programs.

YOU&i Start Program

For new patients with insurance coverage decision delays, Pharmacyclics and Janssen Biotech offer the YOU&i Start Program. This program offers eligible patients who have been prescribed Imbruvica for an FDA-­approved indication, and who are experiencing an insurance coverage decision delay of more than 5 business days, a free 30-day supply of Imbruvica. Under appropriate circumstances, an additional 30-day supply may be provided. The free drug is offered to eligible patients without any purchase contingencies or other obligations.

Independent Foundations

For uninsured patients, the Janssen­affiliated Johnson & Johnson Patient Assistance Foundation, which is an independent, nonprofit organization, may offer assistance with accessing Imbruvica for eligible patients who qualify based on financial need, such as an income requirement of 600% of the federal poverty level.

Application & Enrollment

Enrollment for the YOU&i Support Program can be completed either online, over the phone at 877-877-3536, or by faxing the enrollment form and related information to 800-752-5896.

Table Pharmacyclics Oncology Drug

Patient support programs

Imbruvica (ibrutinib)
Mantle-cell lymphoma after ≥1 previous therapies; marginal-­zone lymphoma in patients ­requiring systemic therapy who received ≥1 anti-­CD20–based therapies; CLL; CLL with 17p deletion; SLL; SLL with 17p ­deletion; Waldenström’s macroglobulinemia; chronic graft-­versus-host disease after failure of ≥1 systemic therapies

CLL indicates chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma.

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: